Search

Your search keyword '"Hiroshige, Tasuku"' showing total 25 results
Start Over Author "Hiroshige, Tasuku"
25 results on '"Hiroshige, Tasuku"'

8. Insights on Platelet-Derived Growth Factor Receptor α-Positive Interstitial Cells in the Male Reproductive Tract.

Author

Hiroshige, Tasuku, Uemura, Kei-Ichiro, Nakamura, Kei-Ichiro, and Igawa, Tsukasa

Subjects
*PLATELET-derived growth factor receptors, *INTERSTITIAL cells, *GERM cells, *MALE reproductive organs, *MALE infertility, *SMOOTH muscle, *SPERM count
Abstract

Male infertility is a significant factor in approximately half of all infertility cases and is marked by a decreased sperm count and motility. A decreased sperm count is caused by not only a decreased production of sperm but also decreased numbers successfully passing through the male reproductive tract. Smooth muscle movement may play an important role in sperm transport in the male reproductive tract; thus, understanding the mechanism of this movement is necessary to elucidate the cause of sperm transport disorder. Recent studies have highlighted the presence of platelet-derived growth factor receptor α (PDGFRα)-positive interstitial cells (PICs) in various smooth muscle organs. Although research is ongoing, PICs in the male reproductive tract may be involved in the regulation of smooth muscle movement, as they are in other smooth muscle organs. This review summarizes the findings to date on PICs in male reproductive organs. Further exploration of the structural, functional, and molecular characteristics of PICs could provide valuable insights into the pathogenesis of male infertility and potentially lead to new therapeutic approaches. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma.

Author

Ueda, Kosuke, Uemura, Keiichiro, Ito, Naoki, Sakai, Yuya, Ohnishi, Satoshi, Suekane, Hiroki, Kurose, Hirofumi, Hiroshige, Tasuku, Chikui, Katsuaki, Nishihara, Kiyoaki, Nakiri, Makoto, Suekane, Shigetaka, Ogasawara, Sachiko, Yano, Hirohisa, and Igawa, Tsukasa

Subjects
IMMUNE checkpoint proteins, RENAL cell carcinoma, PROTEIN expression, APOPTOSIS, MULTIVARIATE analysis, RECEPTOR for advanced glycation end products (RAGE)
Abstract

Immuno-oncology (IO) combination therapy is the first-line treatment for advanced renal cell carcinoma (RCC). However, biomarkers for predicting the response to IO combination therapy are lacking. Here, we investigated the association between the expression of soluble immune checkpoint molecules and the therapeutic efficacy of IO combination therapy in advanced RCC. The expression of soluble programmed cell death-1 (sPD-1), soluble programmed cell death ligand-1 (sPD-L1), soluble PD-L2 (sPD-L2), and lymphocyte activation gene-3 (sLAG-3) was assessed in plasma samples from 42 patients with advanced RCC who received first-line IO combination therapy. All IMDC risk classifications were represented among the patients, including 14.3, 57.1, and 28.6% with favorable, intermediate, and poor risk, respectively. Univariate analysis revealed that prior nephrectomy, sPD-L2 levels, and sLAG-3 levels were significant factors affecting progression-free survival (PFS), whereas multivariate analyses suggested that sPD-L2 and sLAG-3 levels were independent prognostic factors for PFS. In a univariate analysis of the overall survival, prior nephrectomy and sPD-L2 levels were significant factors; no significant differences were observed in the multivariate analysis. No significant correlation was observed between the sPD-L2 and sLAG-3 levels and PD-L2 and LAG-3 expression via immunohistochemistry. In conclusion, sPD-L2 and sLAG-3 expression may serve as a potential biomarker for predicting IO combination therapy efficacy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Sarcopenia and the Therapeutic Effects of Androgen Receptor-axis-targeted Therapies in Patients With Castration-resistant Prostate Cancer

Author

HIROSHIGE, TASUKU, OGASAWARA, NAOYUKI, KUMAGAE, HISAJI, UEDA, KOSUKE, CHIKUI, KATSUAKI, UEMURA, KEI-ICHIRO, NISHIHARA, KIYOAKI, NAKIRI, MAKOTO, MATSUO, MITSUNORI, SUEKANE, SHIGETAKA, and IGAWA, TSUKASA

Subjects
Pharmacology, Cancer Research, General Biochemistry, Genetics and Molecular Biology, Research Article
Abstract

Background/Aim: Sarcopenia is a syndrome characterized by the progressive and generalized loss of skeletal muscle mass and has been reported to be a poor prognostic factor for taxane-treated castration-resistant prostate cancer (CRPC). However, whether sarcopenia affects androgen receptor axis-targeted therapies (ARATs) remains unknown. In the present study, we investigated the association between sarcopenia in CRPC and treatment outcomes of ARATs. Patients and Methods: From January 2015 to September 2022, 127 patients who received ARATs as 1(st)-line treatment for CRPC at our two hospitals were included in the study. We retrospectively evaluated sarcopenia using computed tomography images and investigated whether sarcopenia affects the progression-free survival (PFS) and overall survival (OS) of patients with CRPC treated with ARATs. Results: Out of 127 patients, 99 were diagnosed with sarcopenia. The PFS of the sarcopenic group administered ARATs was significantly better than that of the non-sarcopenic group. Furthermore, in the multivariate analysis of PFS, sarcopenia was an independent favourable prognostic factor. However, there was no significant difference in the OS between the sarcopenic and non-sarcopenia groups. Conclusion: ARATs could more effectively treat patients with CRPC and sarcopenia than patients with CRPC without sarcopenia. Sarcopenia may positively influence the therapeutic effects of ARATs.

Published
2023

11. Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab

Author

Ueda, Kosuke, primary, Ogasawara, Naoyuki, additional, Ito, Naoki, additional, Ohnishi, Satoshi, additional, Suekane, Hiroki, additional, Kurose, Hirofumi, additional, Hiroshige, Tasuku, additional, Chikui, Katsuaki, additional, Uemura, Keiichiro, additional, Nishihara, Kiyoaki, additional, Nakiri, Makoto, additional, Suekane, Shigetaka, additional, and Igawa, Tsukasa, additional

Published
2023
Full Text
View/download PDF

14. Improved Survival of Real-world Japanese Patients With Advanced Renal Cell Carcinoma Treated With Immuno-oncology Combination Therapy

Author

UEDA, KOSUKE, primary, SUEKANE, SHIGETAKA, additional, KUROSE, HIROFUMI, additional, ITO, NAOKI, additional, OGASAWARA, NAOYUKI, additional, HIROSHIGE, TASUKU, additional, CHIKUI, KATSUAKI, additional, EJIMA, KAZUHISA, additional, UEMURA, KEIICHIRO, additional, NAKIRI, MAKOTO, additional, NISHIHARA, KIYOAKI, additional, MATSUO, MITSUNORI, additional, and IGAWA, TSUKASA, additional

Published
2022
Full Text
View/download PDF

18. Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab

Author

Ueda, Kosuke, primary, Suekane, Shigetaka, additional, Kurose, Hirofumi, additional, Ito, Naoki, additional, Ogasawara, Naoyuki, additional, Hiroshige, Tasuku, additional, Chikui, Katsuaki, additional, Ejima, Kazuhisa, additional, Uemura, Keiichiro, additional, Nakiri, Makoto, additional, Nishihara, Kiyoaki, additional, and Igawa, Tsukasa, additional

Published
2022
Full Text
View/download PDF

20. Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab

Author

Ueda, Kosuke, primary, Suekane, Shigetaka, additional, Kurose, Hirofumi, additional, Ogasawara, Naoyuki, additional, Hiroshige, Tasuku, additional, Chikui, Katsuaki, additional, Uemura, Keiichiro, additional, Nakiri, Makoto, additional, Nishihara, Kiyoaki, additional, Matsuo, Mitsunori, additional, and Igawa, Tsukasa, additional

Published
2021
Full Text
View/download PDF

22. Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer

Author

Hiroshige, Tasuku, primary, Eguchi, Yoshiro, additional, Yoshizumi, Osamu, additional, Chikui, Katsuaki, additional, Kumagai, Hisaji, additional, Kawaguchi, Yoshihiro, additional, Onishi, Rei, additional, Hayashi, Tokumasa, additional, Watanabe, Kouta, additional, Mitani, Tomotaro, additional, Saito, Koujiro, additional, and Igawa, Tsukasa, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results